Global Sustained Release Injectables Market by Dosage (In Situ Forming Formulations, In Situ Forming Gel System, In Situ Forming Microparticle Systems), Route of Administration (Interarterial, Intracardiac, Intradermal), End-User - Forecast 2024-2030- Product Image

Sale

Global Sustained Release Injectables Market by Dosage (In Situ Forming Formulations, In Situ Forming Gel System, In Situ Forming Microparticle Systems), Route of Administration (Interarterial, Intracardiac, Intradermal), End-User - Forecast 2024-2030

Report
196 Pages
March 2024
Region: Global
360iResearch™
ID: 5533434

UP TO €851EUR$875USD£729GBP OFF until Dec 31^st 2024

The Sustained Release Injectables Market size was estimated at USD 2.15 billion in 2023, USD 2.29 billion in 2024, and is expected to grow at a CAGR of 6.95% to reach USD 3.45 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Sustained Release Injectables Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Sustained Release Injectables Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Sustained Release Injectables Market, highlighting leading vendors and their innovative profiles. These include Dr. Reddy's Laboratories, GP Pharm S.A., Innocore Pharmaceuticals, Janssen Pharmaceutical Companies by Johnson & Johnson, Novartis AG, Oakwood Laboratories, Pacira Pharmaceuticals, Inc., PhaseBio Pharmaceuticals, Inc, Taiwan Liposome Company (TLC), ViiV Healthcare, and Xbrane Biopharma AB.

Market Segmentation & Coverage

This research report categorizes the Sustained Release Injectables Market to forecast the revenues and analyze trends in each of the following sub-markets:

Dosage
- In Situ Forming Formulations
- In Situ Forming Gel System
- In Situ Forming Microparticle Systems
- Liposome
- Microcapsule
- Microsphere
- Polymeric Micelles
Route of Administration
- Interarterial
- Intracardiac
- Intradermal
- Intramuscular
- Intravenous
- Subcutaneous
End-User
- Diagnostic Laboratories
- Hospitals
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Sustained Release Injectables Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Sustained Release Injectables Market?
What are the technology trends and regulatory frameworks in the Sustained Release Injectables Market?
What is the market share of the leading vendors in the Sustained Release Injectables Market?
Which modes and strategic moves are suitable for entering the Sustained Release Injectables Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Sustained Release Injectables Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of major chronic diseases due to increasing adoption of poor lifestyle habits
5.1.1.2. Rise in demand for paediatric and geriatric sustained release injectables
5.1.1.3. Injectable preparations have a better bioavailability than oral preparations
5.1.2. Restraints
5.1.2.1. Rheological changes during filling, instability on long-term storage and nonadjustable release rate
5.1.3. Opportunities
5.1.3.1. Advancement in technology such as nanotechnology, micronation, and stabilization process
5.1.3.2. Introduction of natural and chemosynthetic biodegradable materials
5.1.4. Challenges
5.1.4.1. High cost of drugs and lack of skilled professionals
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Sustained Release Injectables Market, by Dosage

6.1. Introduction
6.2. In Situ Forming Formulations
6.3. In Situ Forming Gel System
6.4. In Situ Forming Microparticle Systems
6.5. Liposome
6.6. Microcapsule
6.7. Microsphere
6.8. Polymeric Micelles

7. Sustained Release Injectables Market, by Route of Administration

7.1. Introduction
7.2. Interarterial
7.3. Intracardiac
7.4. Intradermal
7.5. Intramuscular
7.6. Intravenous
7.7. Subcutaneous

8. Sustained Release Injectables Market, by End-User

8.1. Introduction
8.2. Diagnostic Laboratories
8.3. Hospitals
8.4. Specialty Clinics

9. Americas Sustained Release Injectables Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Sustained Release Injectables Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Sustained Release Injectables Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. Dr. Reddy's Laboratories
13.1.2. GP Pharm S.A.
13.1.3. Innocore Pharmaceuticals
13.1.4. Janssen Pharmaceutical Companies by Johnson & Johnson
13.1.5. Novartis AG
13.1.6. Oakwood Laboratories
13.1.7. Pacira Pharmaceuticals, Inc.
13.1.8. PhaseBio Pharmaceuticals, Inc
13.1.9. Taiwan Liposome Company (TLC)
13.1.10. ViiV Healthcare
13.1.11. Xbrane Biopharma AB
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. SUSTAINED RELEASE INJECTABLES MARKET RESEARCH PROCESS
FIGURE 2. SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2023 VS 2030
FIGURE 3. SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. SUSTAINED RELEASE INJECTABLES MARKET DYNAMICS
FIGURE 7. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2023 VS 2030 (%)
FIGURE 8. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. SUSTAINED RELEASE INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. SUSTAINED RELEASE INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. SUSTAINED RELEASE INJECTABLES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 6. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IN SITU FORMING FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IN SITU FORMING GEL SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IN SITU FORMING MICROPARTICLE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY LIPOSOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY MICROCAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY MICROSPHERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMERIC MICELLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 14. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTERARTERIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRACARDIAC, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 21. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 35. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 38. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 45. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. AUSTRALIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 49. AUSTRALIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. AUSTRALIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 52. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 55. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. INDONESIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 58. INDONESIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. INDONESIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 61. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. MALAYSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 64. MALAYSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. MALAYSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. PHILIPPINES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 67. PHILIPPINES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. PHILIPPINES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. SINGAPORE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 70. SINGAPORE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. SINGAPORE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. SOUTH KOREA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 73. SOUTH KOREA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. SOUTH KOREA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. TAIWAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 76. TAIWAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. TAIWAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. THAILAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 79. THAILAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. THAILAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. VIETNAM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 82. VIETNAM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. VIETNAM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 88. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 89. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 92. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 95. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 98. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 101. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 104. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 107. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 110. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 113. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 116. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 119. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 122. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 128. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 134. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 137. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 140. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 143. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. SUSTAINED RELEASE INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 152. SUSTAINED RELEASE INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 153. SUSTAINED RELEASE INJECTABLES MARKET LICENSE & PRICING

Companies Mentioned

Dr. Reddy's Laboratories
GP Pharm S.A.
Innocore Pharmaceuticals
Janssen Pharmaceutical Companies by Johnson & Johnson
Novartis AG
Oakwood Laboratories
Pacira Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc
Taiwan Liposome Company (TLC)
ViiV Healthcare
Xbrane Biopharma AB

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	196
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 2.29 Billion
Forecasted Market Value ( USD ) by 2030	$ 3.45 Billion
Compound Annual Growth Rate	6.9%
Regions Covered	Global
No. of Companies Mentioned	11

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3283EUR$3,374USD£2,812GBP €3648EUR$3,749USD£3,125GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4159EUR$4,274USD£3,562GBP €4621EUR$4,749USD£3,958GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5034EUR$5,174USD£4,313GBP €5594EUR$5,749USD£4,792GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5910EUR$6,074USD£5,063GBP €6567EUR$6,749USD£5,625GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7661EUR$7,874USD£6,563GBP €8513EUR$8,749USD£7,292GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Sustained Release Injectables Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis

Chronic Disease Markets for Sustained Released Injectables

Global Generic Injectables Market by Product (Large Molecule Injectables, Small Molecule Injectables), Type (Cytokines, Insulin, Monoclonal Antibodies), Application, Distribution Channel - Forecast 2024-2030

Global Injectable Drugs Market by Molecule Type (Large Molecule, Small Molecule), Drug Class (Blood Factors, Cytokines, Immunoglobulin), Injection Routes, Application - Forecast 2023-2030

Sterile Injectable Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

About the Market